Quantcast

Latest Xyrem Stories

2014-08-05 16:27:58

Company Reports Second Quarter 2014 Total Revenues of $291 Million, Driven by Strong Sales of Xyrem, Erwinaze and Defitelio DUBLIN, Aug. 5, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter ended June 30, 2014 and updated financial guidance for 2014. "Strong underlying demand for our products and the start of our European Union launch of Defitelio led to significant revenue growth in the second quarter," said Bruce C. Cozadd,...

2014-08-05 16:27:45

Jazz Pharmaceuticals owns worldwide rights to defibrotide DUBLIN, Aug. 5, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the closing of its acquisition of rights to defibrotide in the United States (U.S.) and all other countries in the Americas from Sigma-Tau Pharmaceuticals, Inc. (Sigma-Tau). Jazz Pharmaceuticals now owns worldwide rights to defibrotide. Defibrotide is a novel product that is marketed by Jazz Pharmaceuticals in the European Union (EU)...

2014-08-04 16:26:45

DUBLIN, Aug. 4, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the Canaccord Genuity 34(th) Annual Growth Conference in Boston, MA on Wednesday, August 13, 2014 at 9:00 a.m. EDT / 2:00 p.m. IST. Bruce Cozadd, chairman and chief executive officer, will provide an overview of the company and a business and financial update. A live audio webcast of the presentation may be accessed from the...

2014-07-22 16:27:22

DUBLIN, July 22, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2014 second quarter financial results on Tuesday, August 5, 2014, after the close of the financial markets. Company management will host a live audio webcast immediately following the announcement at 4:30 p.m. EDT/9:30 p.m. IST to provide a business and financial update and discuss second quarter 2014 financial results. Interested parties may access the live audio...

2014-07-02 08:27:01

Jazz Pharmaceuticals to own worldwide rights to defibrotide at closing DUBLIN, July 2, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company has signed a definitive agreement with Sigma-Tau Pharmaceuticals, Inc. (Sigma-Tau) under which a subsidiary of Jazz Pharmaceuticals plc (Jazz) will acquire from Sigma-Tau rights to defibrotide in the United States (U.S.) and all other countries in the Americas. Sigma-Tau holds rights to market...

2014-06-02 16:25:34

Study Demonstrated Robust Alerting Effect Consistent with Phase 2a Results DUBLIN, June 2, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today presented data from the Phase 2b study evaluating JZP-110 (formerly known as ADX-N05) as a potential new treatment for the symptoms of excessive daytime sleepiness (EDS) in adults with narcolepsy. In the study, all primary and secondary endpoints were met and patients treated with JZP-110 experienced statistically significant...

2014-05-27 16:25:39

Phase 2b Data for JZP-110 in Adults with EDS in Narcolepsy Accepted as Late-Breaker Oral Presentation DUBLIN, May 27, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that new data for the investigational compound JZP-110 (previously ADX-N05) will be presented at the 28th Associated Professional Sleep Societies (APSS) Annual SLEEP Meeting, May 31 to June 4, 2014 in Minneapolis, Minn. The JZP-110 abstract was accepted as a late-breaker oral presentation. The...

2014-05-13 20:23:14

DUBLIN, May 13, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentations at two upcoming investor conferences. -- UBS Global Healthcare Conference in New York, NY on Tuesday, May 20, 2014 at 8:00 a.m. EDT / 1:00 p.m. IST. Matt Young, senior vice president and chief financial officer, will provide an overview of the company and a business and financial update. -- Goldman...

2014-04-24 16:29:35

DUBLIN, April 24, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2014 first quarter financial results on Thursday, May 8, 2014, after the close of the financial markets. Company management will host a live audio webcast immediately following the announcement at 4:30 p.m. EDT/9:30 p.m. IST to provide a business and financial update and discuss first quarter 2014 financial results. Interested parties may access the live audio...

2014-03-31 08:29:52

Defitelio®? (defibrotide) Launch Announced During the 40th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 2014 DUBLIN and VILLA GUARDIA, Italy, March 31, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Gentium S.p.A., a Jazz Pharmaceuticals company, today announced the commencement of the European commercial launch of Defitelio®(?) (defibrotide), the first licensed product for the treatment of severe hepatic veno-occlusive...


Word of the Day
caparison
  • A cloth or covering, more or less ornamented, laid over the saddle or furniture of a horse, especially of a sumpter-horse or horse of state.
  • Clothing, especially sumptuous clothing; equipment; outfit.
  • To cover with a caparison, as a horse.
  • To dress sumptuously; adorn with rich dress.
This word ultimately comes from the Medieval Latin 'cappa,' cloak.
Related